GlobeNewswire: Hemispherx Biopharma, Inc. Contains the last 10 of 194 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T10:23:05ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2014/12/09/689822/10111624/en/Hemispherx-Announces-Data-Showing-Inhibition-of-Ebola-by-Ampligen-R-Enlarged-by-Howard-University-Research.html?f=22&fvtc=4&fvtv=7188Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research2014-12-09T14:51:57Z<![CDATA[Independent Demonstration of Anti-Ebola Function of Hemispherx's Biotherapeutic PHILADELPHIA, Dec. 9, 2014 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2013/12/16/597065/10061529/en/Centers-for-Disease-Control-Urges-Preparation-for-an-Active-Seasonal-Flu-Season.html?f=22&fvtc=4&fvtv=7188Centers for Disease Control Urges Preparation for an Active Seasonal Flu Season2013-12-16T13:30:00Z<![CDATA[Hemispherx Biopharma Accelerates Program to Evaluate Ampligen(R)/FluMist(R) Combination as Potential Intranasal Influenza Vaccine Against Pandemic Flu Strains PHILADELPHIA, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced that the company will accelerate its experimental program for a new intranasal influenza vaccine combination following a media briefing by the Centers for Disease Control (CDC) urging Americans, especially young children and the elderly, to get vaccinated for the emerging flu season immediately (CDC, December 12, 2013), coincidental with National Influenza Vaccination Week.]]>https://www.globenewswire.com/news-release/2013/12/09/595439/10060739/en/FDA-Authorizes-Expansion-of-Ampligen-FluMist-Intranasal-Clinical-Trial-Designed-to-Elicit-Potential-Protection-Against-Many-Pre-Pandemic-Influenza-Viruses.html?f=22&fvtc=4&fvtv=7188FDA Authorizes Expansion of Ampligen/FluMist Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses2013-12-09T13:00:00Z<![CDATA[Data Monitoring Committee Also Supports Expansion of Clinical Tests PHILADELPHIA, Dec. 9, 2013 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2013/12/04/594476/10060327/en/Hemispherx-Biopharma-Appoints-New-Chief-Financial-and-Chief-Accounting-Officers.html?f=22&fvtc=4&fvtv=7188Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers2013-12-04T12:30:00Z<![CDATA[Seasoned Executives in Financial and Accounting Matters With International Experience PHILADELPHIA, Dec. 4, 2013 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2013/12/02/593767/10059919/en/Hemispherx-Biopharma-and-the-University-of-Pittsburgh-Collaborate-on-a-Novel-Chemokine-Modulatory-Program-for-Cancer-Immunotherapies-With-Ampligen-R-as-a-Key-Component.html?f=22&fvtc=4&fvtv=7188Hemispherx Biopharma and the University of Pittsburgh Collaborate on a Novel Chemokine-Modulatory Program for Cancer Immunotherapies With Ampligen(R) as a Key Component2013-12-02T12:30:00Z<![CDATA[PHILADELPHIA, Dec. 2, 2013 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2013/11/19/590929/10058355/en/Hemispherx-Biopharma-Sponsors-Chronic-Fatigue-Syndrome-Conference-at-Mount-Sinai-Medical-Center-in-New-York.html?f=22&fvtc=4&fvtv=7188Hemispherx Biopharma Sponsors Chronic Fatigue Syndrome Conference at Mount Sinai Medical Center in New York2013-11-19T13:00:00Z<![CDATA[PHILADELPHIA, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its sponsorship of the Conference on "Diagnosis, Treatments and New Developments in ME and CFS" ("Myalgic Encephalomyelitis" and "Chronic Fatigue Syndrome") which will be held on November 20th beginning at 11 AM (EST) at the New York Academy of Medicine, 1215 Fifth Avenue/103]]>https://www.globenewswire.com/news-release/2013/11/08/588431/10057173/en/Hemispherx-Biopharma-Announces-Financial-Results-for-the-Three-Months-Ended-September-30-2013.html?f=22&fvtc=4&fvtv=7188Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 20132013-11-08T21:24:49Z<![CDATA[Qualification Phase for Alferon(R) Manufacturing Underway PHILADELPHIA, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended September 30, 2013. The net loss (including non-cash effects) was approximately $5,136,000 or $(0.03) per share as compared to a net loss of $6,587,000 or ($0.05) per share for the same three month period in 2012. This Quarter-to-Quarter decrease in net loss of approximately $1,451,000 was predominantly caused by:]]>https://www.globenewswire.com/news-release/2013/10/18/581614/10053295/en/Hemispherx-Biopharma-Reports-on-Annual-Stockholder-Meeting.html?f=22&fvtc=4&fvtv=7188Hemispherx Biopharma Reports on Annual Stockholder Meeting2013-10-18T17:10:18Z<![CDATA[PHILADELPHIA, Oct. 18, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE MKT:HEB) announced that it held its 2013 Annual Meeting of Stockholders on October 18, 2013. Final voting results will be included in an 8-K to be filed later today. ]]>https://www.globenewswire.com/news-release/2013/10/03/578045/10051178/en/Hemispherx-Biopharma-s-2013-Stockholder-Annual-Meeting-Proposal-4-Removed-From-Stockholder-Consideration.html?f=22&fvtc=4&fvtv=7188Hemispherx Biopharma's 2013 Stockholder Annual Meeting Proposal 4 Removed From Stockholder Consideration2013-10-03T17:46:49Z<![CDATA[PHILADELPHIA, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company") announced that its Board of Directors has decided not to seek Stockholder approval regarding the proposed HEMISPHERx 2013 Equity Incentive Plan (the "Plan") and has withdrawn this proposal from the agenda for its Annual Meeting scheduled for October 18, 2013.]]>https://www.globenewswire.com/news-release/2013/09/18/574352/10049050/en/Hemispherx-Biopharma-s-2013-Stockholder-Annual-Meeting-Set.html?f=22&fvtc=4&fvtv=7188Hemispherx Biopharma's 2013 Stockholder Annual Meeting Set2013-09-18T20:30:00Z<![CDATA[PHILADELPHIA, Sept. 18, 2013 (GLOBE NEWSWIRE) -- ]]>